Indications for Hormone Therapy post treatment of DCIS:
- High risk DCIS (high grade, comedo-necrosis)
- MUST be ER/PR +
- Patient had lumpectomy not Mastectomy
- Not for Pleomorphic LCIS
Pre-menopausal women: Tamoxifen for 5 years
Post-menopausal women: Tamoxifen or an Aromatase Inhibitor for 5 years.
NOTE: Hormone treatment does NOT improve survival but it may decrease local recurrence in the treated breast as well as the other breast.
Learn more about hormone therapy and how certain hormones can affect cancer cells.
Learn more about the benefits and risks of hormone therapy. If you have had hormone therapy, learn about how to reduce these risks.
Learn about various forms of breast cancer treatment such as neoadjuvant chemotherapy, hormone therapy, targeted therapy and immunotherapy.
Information on Tamoxifen and Aromatase Inhibitors:
Learn about hormone therapies, including Tamoxifen and Toremifene (Fareston). Please note that Toremifene has only been approved to treat postmenopausal women with metastatic breast cancer.
Learn more about how Tamoxifen can lower the onset and recurrence of breast cancer.
Hormonal Therapy for Breast Cancer: We Teach You
Learn more about hormonal therapy for breast cancer.
Adjuvant Hormonal Therapy for Estrogen Receptor Positive Early Stage Breast Cancer – Mayo Clinic
Learn about how Tamoxifen can be used to treat premenopausal or postmenopausal women with estrogen-receptor positive breast cancer, whereas aromatase inhibitors are only used to treat postmenopausal women with estrogen-receptor positive breast cancer. Also learn of the side effects of both.